^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    APP-NRG1 fusion

    i
    Other names: Amyloid Beta Precursor Protein, Amyloid Beta (A4) Precursor Protein, Alzheimer Disease Amyloid Protein, Cerebral Vascular Amyloid Peptide, Amyloid-Beta Precursor Protein, Amyloid Precursor Protein, Peptidase Nexin-II, Protease Nexin-II, PreA4, ABPP,Beta-Amyloid Precursor Protein, Testicular Tissue Protein Li, Beta-Amyloid Peptide(1-40), Beta-Amyloid Peptide(1-42), Amyloid Beta A4 Protein, CTFgamma, NRG1, GGF, HGL, HRG, NDF, NRG1-IT2, Neuregulin 1, Heregulin
    Entrez ID:
    3084; 351
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost4years
    [VIRTUAL] Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions (AACR 2021)
    There was no shrinkage of afatinib-treated pancreatic PDX tumors.Our results here suggest that seribantumab is effective at reducing tumor growth in preclinical models of gastrointestinal cancers with NRG1 fusions. These data support the use of seribantumab to treat GI and other cancers with NRG1 fusions in the ongoing phase 2 CRESTONE study (NCT#04383210).
    Preclinical
    |
    NRG1 (Neuregulin 1) • SLC3A2 (Solute Carrier Family 3 Member 2) • ATP1B1 (ATPase Na+/K+ transporting subunit beta 1) • EGF (Epidermal growth factor)
    |
    ERBB3 expression • NRG1 fusion • ATP1B1-NRG1 fusion • SLC3A2-NRG1 fusion • APP-NRG1 fusion
    |
    Gilotrif (afatinib) • seribantumab (MM-121)
    over4years
    [VIRTUAL] 9F7-F11, a non-competing anti-HER3 antibody with allosteric potentiation by NRG1, eradicates in vivo tumors with NRG1 fusion and offers new perspectives for treating NRG1-dependent tumors (AACR-II 2020)
    Tumor responses have been observed with tyrosine kinase inhibitors afatinib and tarloxotinib, but durable responses are rare and emergence of toxicity and resistance to these drugs could not be avoided...In vivo activity of 9F7-F11 was evaluated in comparison to MM121 using xenograft models with MDA-MB-175 breast cancer cell line or CTG-0943 patient-derived pancreatic tumor bearing respectively DOC4-NRG1 and APP-NRG1 fusion... 9F7-F11 antibody displays a unique potential for targeted treatment of NRG1-positive cancers. 9F7-F11 binding to HER3 is promoted by the ligand NRG1. This binding property was translated in vivo by an outstanding activity against xenograft models bearing NRG1 fusion, characterized by 100% of eradicated tumors.
    Preclinical
    |
    NRG1 (Neuregulin 1)
    |
    NRG1 fusion • APP-NRG1 fusion
    |
    Gilotrif (afatinib) • seribantumab (MM-121) • Tarlox (tarloxotinib bromide)